The Aesthetics Advisor

Rapid weight loss drugs continue to surge in popularity, making them the major contributor to the 13.5% increase in spending on prescription medications in the U.S. in 2023, according to a report1 from the American Journal of Health-System Pharmacy. Leading this trend is semaglutide, better known by its brand names Ozempic, a diabetes medication, and Wegovy, a higher-dose variant specifically for weight loss. Both drugs come from the Danish pharmaceutical company Novo Nordisk, whose market capitalization has soared to $609 billion, surpassing Tesla’s valuation by $40 billion. (2) However, with the increasing demand for these drugs comes more reports of users experiencing a range of unexpected and concerning changes to their bodies, from loose skin to sunken cheeks colloquially termed " Ozempic face ." The latest reported side effect to join the growing list is saggy breast, aka "Ozempic breast." Ozempic Use Now Linked to ‘Deflated’ Breasts Taking semaglutide doesn...